Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Mitochondrial Disease and Oncology Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CLUH drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CLUH Recombinant Protein (TPR Domain / Full Length) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli or HEK293 expressed. |
View CLUH Products |
| Gene Delivery | CLUH Promise-ORF / Lentivirus Full-length ORF for stable cell lines to study mitochondrial clustering and translation. |
View CLUH Products |
| Benchmark Ab | Anti-CLUH Antibody Recombinant positive control for Western Blot, Immunoprecipitation, and Immunofluorescence. |
View CLUH Products |
| Validator | CLUH siRNA Set For knockdown verification in mitochondrial morphology and translation assays. |
View CLUH Products |
| Related Target A | PINK1 Critical partner in mitophagy and mitochondrial quality control pathway. |
View PINK1 Products |
| Related Target B | PPARGC1A Master regulator of mitochondrial biogenesis, functionally linked to CLUH-mediated translation. |
View PPARGC1A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| In vitro RNA-binding activity verification | RNase-free recombinant CLUH protein with conserved RNA-binding domain, sequence verified by MS. |
| Mitochondrial clustering phenotype screening | Lentivirus Premade Particles for stable cell line construction to monitor mitochondrial distribution. |
| Lack of Controls | Sequence-verified clinical-grade benchmark antibodies included. |
| False Positives | Validated siRNA pool included for specificity and target knockdown checks. |
Live CLUH R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CLUH (Clustered mitochondria homolog) therapeutics is intensifying, with major players shifting focus from traditional systemic metabolic modulators to targeted RNA-binding protein (RBP) small molecules and genetic medicines. As first-generation therapies targeting mitochondrial dynamics reach early-stage preclinical validation, the next wave of R&D is targeting CLUH's unique role in metabolic reprogramming in cancer and neurodegenerative diseases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule / PROTAC | Biotech Startups, Academic Consortia | Neurodegenerative Diseases (e.g., Parkinson's), Oncology | Binding Affinity & Selectivity Assay (Need high-purity mutant and WT CLUH proteins) |
| RNAi / Antisense Oligonucleotides | Mitochondrial Medicine Specialists | Mitochondrial Myopathies, Metabolic Syndromes | Target Knockdown & Functional Phenotype Validation (Need validated siRNA and Lentivirus) |
| Gene Therapy | Rare Disease Therapeutics Developers | Hereditary Spastic Paraplegia, Mitochondrial Disorders | Overexpression Stability & Morphology Assays (Need high-titer Lentiviral vectors) |